I
The startup develops antibody drugs targeting autoimmune diseases caused by abnormalities in the complement regulatory system, with a focus on conditions that lead to the destruction of red blood cells. Their proprietary platform also provides therapeutic solutions for diabetic retinal diseases and dry age-related macular degeneration, addressing significant gaps in treatment options for these conditions.
Seoul, South Korea
Updated 2 months ago
Funding
$24.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antibody drugs targeting autoimmune diseases caused by abnormalities in the complement regulatory system, with a focus on conditions that lead to the destruction of red blood cells. Their proprietary platform also provides therapeutic solutions for diabetic retinal diseases and dry age-related macular degeneration, addressing significant gaps in treatment options for these conditions.